Systematic review · 2025 · Disease-a-month : DM
Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review. (opens in a new tab)
Found a benefit
Tolebrutinib and evobrutinib, two oral drugs, reduced brain inflammation and relapses in relapsing MS with generally mild side effects, though more trials are needed.
From the abstract
With good safety and efficacy profiles in treating relapsing multiple sclerosis, both of the BTKis (Evobrutinib and Tolebrutinib) show promise.
Tagged by software from the title and abstract. The quote is copied word for word.